VetCell Biotechnology

VetCell Biotechnology, also known as VetCell Therapeutics Asia, is a regenerative medicine company specializing in the development of cell-based therapies for companion animals. As a subsidiary of PrimeGen Global, the company utilizes a proprietary stem cell activation platform, stemXcell, to produce high-potency mesenchymal stem cells (MSCs) and MSC-derived exosomes. Its primary focus is on treating chronic inflammatory and degenerative conditions, including canine osteoarthritis, feline chronic gingivostomatitis (FCGS), and canine atopic dermatitis. The company maintains GMP-compliant research and manufacturing facilities in Foshan, China, and Santa Ana, California, and is actively conducting clinical trials to seek regulatory approvals for its veterinary biologics.